Professor Benedikt Kessler and Dr Adan Pinto-Fernandez from Oxford’s Target Discovery Institute were part of this study.
New structural insights accelerate drug discovery in the ubiquitin system for cancer therapy
18 October 2017
A multi-disciplinary research team from the Universities of Oxford, MRC LMB, Liverpool, Cancer Research UK and pharma (Forma Therapeutics) has performed structural studies of USP7 inhibitor-enzyme interactions, demonstrating that ubiquitin-specific proteases (USPs) are tractable drug targets for cancer and also other diseases.
